NCT05609812 (COMPASS) is a Phase 3 clinical trial of Atacicept in Lupus Nephritis (LN), sponsored by Vera Therapeutics, Inc..

Who is sponsoring NCT05609812?

NCT05609812 is sponsored by Vera Therapeutics, Inc..

What drugs are being tested in NCT05609812?

Interventions in NCT05609812: Atacicept, Placebo.

What condition does NCT05609812 study?

NCT05609812 studies Lupus Nephritis (LN).

Is NCT05609812 still recruiting?

NCT05609812 is currently withdrawn. Last updated 23 May 2025.

Last reviewed 2025-05-23 · How we verify

NCT05609812: COMPASS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Atacicept in Subjects With Active Lupus Nephritis (COMPASS)

Withdrawn Phase 3 Last updated 23 May 2025

What this trial tests

Phase 3 trial testing Atacicept in Lupus Nephritis (LN). Withdrawn.

Timeline

2 November 2022

Primary endpoint
15 March 2026

15 December 2028

Quick facts

Lead sponsor	Vera Therapeutics, Inc.
Phase	Phase 3
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Start date	2 November 2022
Primary completion	15 March 2026
Estimated completion	15 December 2028
Sites	33 locations across Puerto Rico, United States, Spain

Drugs / interventions tested

Atacicept — full drug profile →
Placebo

Conditions studied

Lupus Nephritis (LN) — all drugs for Lupus Nephritis (LN) →

Sponsor

Vera Therapeutics, Inc.

Who can join

Adults 18 to 75, any sex, with Lupus Nephritis (LN). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of the study is to evaluate the effect of atacicept compared to placebo on changes to renal response in adult subjects with LN.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Targeted therapies for lupus nephritis: Current perspectives and future directions.
Jia X, Lu Y, Zheng X, Tang R, et al · · 2024 · cited 8× · PMID 38057972 · DOI 10.1097/cm9.0000000000002959
Targeted Therapy for SLE-What Works, What Doesn't, What's Next.
Venturelli V, Isenberg DA. · · 2023 · cited 8× · PMID 37176637 · DOI 10.3390/jcm12093198
The role of B cell-activating factor system in autoimmune diseases: mechanisms, disease implications, and therapeutic advances.
Li L, Shen S, Shao S, Dang E, et al · · 2025 · cited 4× · PMID 40547016 · DOI 10.3389/fimmu.2025.1538555
Promising Experimental Treatments for Lupus Nephritis: Key Talking Points and Potential Opportunities.
Neves A, Viveiros L, Venturelli V, Isenberg DA. · · 2023 · cited 4× · PMID 37456804 · DOI 10.2147/rru.s385836
Systematic Review of Trial Design and End Points in Lupus Nephritis.
Giang S, Dall'Era MA, Jones RB, Lightstone L, et al · · 2026 · PMID 42006208 · DOI 10.1016/j.ekir.2026.106479
CAR-T Cell Therapy for Autoimmune Kidney Diseases: Where Do We Stand Now?
Kaleta B. · · 2025 · PMID 41155362 · DOI 10.3390/ijms262010070

Verify or expand the search:

Other recruiting trials for Lupus Nephritis (LN)

Currently open trials in the same condition.

NCT07491900 — A Phase 1 Study of HB2198 in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE) · Phase 1 · recruiting
NCT06975787 — Dose Escalation Study With Bispecific Antibodies in Adult Patients With Lupus Nephritis · Phase 1 · recruiting
NCT07236762 — An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases · Phase 1 · recruiting
NCT07363460 — Study to Assess Efficacy and Safety of HSK39297 Tablets in Patients With LN · Phase 2 · recruiting
NCT07123519 — A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases · Phase 1 · recruiting

Other Vera Therapeutics, Inc. trials

Trials by the same sponsor.

NCT06674577 — A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept · Phase 2 · enrolling by invitation
NCT04294472 — A Safety, Pharmacokinetics and Efficacy Study of MAU868 for the Treatment of BK Viremia in Kidney Transplant Recipients · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05609812 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Vera Therapeutics, Inc.
Last refreshed: 23 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05609812.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing